Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?

被引:4
|
作者
Boerner, Thomas [1 ]
Zambirinis, Constantinos [1 ]
Gagniere, Johan [1 ,4 ,5 ]
Chou, Joanne F. [2 ]
Gonen, Mithat [2 ]
Kemeny, Nancy E. [3 ]
Cercek, Andrea [3 ]
Connell, Louise C. [3 ]
Kingham, Thomas P. [1 ]
Allen, Peter J. [1 ,6 ]
Balachandran, Vinod P. [1 ]
Drebin, Jeffrey [1 ]
Jarnagin, William R. [1 ]
D'Angelica, Michael, I [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[4] Clermont Auvergne Univ, Univ Hosp Clermont Ferrand, Dept Digest & Hepatobiliary Surg, Clermont Ferrand, France
[5] Clermont Auvergne Univ, U1071 Inserm, Clermont Ferrand, France
[6] Duke Univ, Dept Surg, Durham, NC USA
基金
美国国家卫生研究院;
关键词
HEPATIC ARTERIAL INFUSION; RANDOMIZED PHASE-III; COLON-CANCER; POOLED ANALYSIS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; RESECTION; SURVIVAL; COMBINATION;
D O I
10.1016/j.hpb.2020.08.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM ( 12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan?Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44?0.94, p = 0.022) and allcause mortality (HRadj: 0.54, 95%CI:0.36?0.81, p = 0.003) compared to Surgery alone patients. Largest tumor 5 cm (HRadj: 2.03, 95%CI: 1.41?2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29?2.89, p = 0.002) were independently associated with worse OS. Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM (<12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44-0.94, p = 0.022) and all cause mortality (HRadj: 0.54, 95%CI:0.36-0.81, p = 0.003) compared to Surgery alone patients. Largest tumor >5 cm (HRadj: 2.03, 95%CI: 1.41-2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29-2.89, p = 0.002) were independently associated with worse OS. Conclusion: Adjuvant HAIC + Sys after resection of early CLM that occur after chemotherapy for node positive primary is associated with improved outcomes.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 50 条
  • [1] Significance of Neoadjuvant and Adjuvant Chemotherapy for Colorectal Liver Metastases
    Koehne, Claus-Henning
    Schumann-Binarsch, Silke
    VISZERALMEDIZIN, 2012, 28 (01): : 28 - 33
  • [2] Nutritional status predicts adjuvant chemotherapy outcomes for stage III colorectal cancer
    Ihara, Keisuke
    Yamaguchi, Satoru
    Shida, Yosuke
    Fujita, Junki
    Matsudera, Shotaro
    Kikuchi, Maiko
    Muroi, Hiroto
    Nakajima, Masanobu
    Sasaki, Kinro
    Tsuchioka, Takashi
    Kojima, Kazuyuki
    JOURNAL OF THE ANUS RECTUM AND COLON, 2019, 3 (02): : 78 - 83
  • [3] Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer
    Hoshino, Nobuaki
    Kawada, Kenji
    Hida, Koya
    Goto, Saori
    Uozumi, Ryuji
    Hasegawa, Suguru
    Sugihara, Kenichi
    Sakai, Yoshiharu
    MEDICAL ONCOLOGY, 2017, 34 (08)
  • [4] Role of Adjuvant Therapy After Resection of Colorectal Cancer Liver Metastases
    Power, Derek G.
    Kemeny, Nancy E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2300 - 2309
  • [5] Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?
    Esch, Anouk
    Coriat, Romain
    Perkins, Geraldine
    Brezault, Catherine
    Chaussade, Stanislas
    PRESSE MEDICALE, 2012, 41 (01): : 51 - 57
  • [6] Prophylactic Adjuvant Hepatic Arterial Infusion Chemotherapy Reduced Hepatic Metastases from Stage III Colorectal Cancer after Curative Resection
    Feng, Wen Ming
    Tang, Cheng Wu
    Huang, San Xiong
    Zheng, Yin Yuan
    Bao, Ying
    Wang, Yao
    Tao, Yu Long
    HEPATO-GASTROENTEROLOGY, 2012, 59 (116) : 1087 - 1090
  • [7] The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity
    Wildes, Tanya M.
    Kallogjeri, Dorina
    Powers, Brian
    Vlahiotis, Anna
    Mutch, Matthew
    Spitznagel, Edward L., Jr.
    Tan, Benjamin
    Piccirillo, Jay F.
    JOURNAL OF GERIATRIC ONCOLOGY, 2010, 1 (02) : 48 - 56
  • [8] Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
    Chen, Xin
    Tu, Junhao
    Xu, Xiaolan
    Gu, Wen
    Qin, Lei
    Qian, Haixin
    Jia, Zhenyu
    Ma, Chuntao
    Xu, Yinkai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
    Grothey, A.
    Sobrero, A. F.
    Shields, A. F.
    Yoshino, T.
    Paul, J.
    Taieb, J.
    Souglakos, J.
    Shi, Q.
    Kerr, R.
    Labianca, R.
    Meyerhardt, J. A.
    Vernerey, D.
    Yamanaka, T.
    Boukovinas, I.
    Meyers, J. P.
    Renfro, L. A.
    Niedzwiecki, D.
    Watanabe, T.
    Torri, V.
    Saunders, M.
    Sargent, D. J.
    Andre, T.
    Iveson, T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) : 1177 - 1188
  • [10] Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older
    van Erning, F. N.
    Creemers, G. J.
    De Hingh, I. H. J. T.
    Loosveld, O. J. L.
    Goey, S. H.
    Lemmens, V. E. P. P.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2839 - 2844